Investor Relations

Select Pipeline Products

Lilly currently has an unprecedented number of molecules in clinical development. The company is generating potential biotech solutions alongside more traditional chemistry-based work in order to deliver innovative treatments for a wide range of diseases, including cancer, multiple sclerosis, diabetes, osteoporosis, rheumatoid arthritis, and Alzheimer's disease.

One of Lilly's most promising areas of research and development concerns personalized medicine, more broadly defined as tailored therapies. The ultimate goal is to provide the right medicine, at the right time, at the right dose, for patients.

For a look at the unique molecules in Lilly's clinical development pipeline, please click here.